Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 5:9:126.
doi: 10.3389/fonc.2019.00126. eCollection 2019.

Chimeric Antigen Receptors for T-Cell Malignancies

Lauren D Scherer  1   2 , Malcolm K Brenner  1   2   3 , Maksim Mamonkin  1   2   3   4
Affiliations
Review

Chimeric Antigen Receptors for T-Cell Malignancies

Lauren D Scherer et al. Front Oncol. .

Abstract

Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.

Keywords: T cell malignancy; T-cells; chimeric antigen receptors (CARs); immunotherapy; non-Hodgkin lymphoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Challenges associated with the development of CARs for T-cell malignancies and main strategies to overcome these limitations.
See this image and copyright information in PMC

References

    1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. (2002) 108:153–64. 10.1016/S0092-8674(02)00625-6 - DOI - PubMed
    1. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. . Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. (2011) 118:874–83. 10.1182/blood-2010-06-292615 - DOI - PMC - PubMed
    1. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, et al. . A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. (2012) 14:830–40. 10.3109/14653249.2012.671519 - DOI - PubMed
    1. Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. . Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. (2018) 36:2926–34. 10.1200/JCO.2018.77.7250 - DOI - PMC - PubMed
    1. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. (2011) 2011:623924. 10.5402/2011/623924 - DOI - PMC - PubMed

LinkOut - more resources